The pharmacology of VA21B7: an atypical 5-HT 3 receptor antagonist with anxiolytic-like properties in animal models

The pharmacology of VA21B7: an atypical 5-HT 3 receptor antagonist with anxiolytic-like... 213 117 117 2 2 I. Artaiz G. Romero A. Zazpe B. Lasheras J. Del Río A. Monge J. M. Calderó J. Roca Department of Pharmacology, Schools of Medicine and Pharmacy University of Navarra Apdo. 273 E-31080 Pamplona Spain Department of Organic Chemistry, CIFA University of Navarra E-31080 Pamplona Spain Vita Research Department Barcelona Spain Abstract VA21B7 (3-(2-(4′-piperonylpiperazinyl) indolyl) carboxaldehyde) was synthesized as a potential 5-HT 3 receptor antagonist. Even though VA21B7 showed a higher affinity towards 5-HT 3 receptors as compared to other receptors studied, it was not a potent 5-HT 3 receptor antagonist either in the periphery or in the brain. In a simple animal model of anxiety such as the two-compartment box in mice, a remarkable anxiolytic-like effect was found at doses of 2–500 µg/kg IP and also at low oral doses, in the microgram range. These drug doses did not produce any significant effect on spontaneous motor activity of mice. The anxiolytic profile of VA21B7 was further explored using other models of anxiety in rats such as the elevated plus-maze and punished-drinking. VA21B7 was compared with standard 5-HT 3 receptor antagonists such as ondansetron, tropisetron and granisetron, with the 5-HT 1A agent buspirone and with diazepam. In the plus-maze, VA21B7 showed an anxiolytic-like profile after doses of 0.25–0.5 mg/kg IP or 2–4 mg/kg PO which did not modify the number of total entries into the open and closed arms of the maze. Diazepam, granisetron and tropisetron were also effective in this test but not ondansetron and buspirone. VA21B7 was also able to release suppressed behaviour in the punished-drinking test. The dose-response curve was bell-shaped with a peak at 2–4 mg/kg. At variance with other studies, 5-HT 3 receptor antagonists also increased the number of shocks taken in this test and the dose-response curve was also bell-shaped. VA21B7 was not anticonvulsant like diazepam, its anxiolytic action in the light/dark test was not flumazenil-sensitive and there was no rebound anxiogenic effect on withdrawal from chronic VA21B7 treatment for 15 consecutive days. Moreover, VA21B7 was not amnesic like the benzodiazepines but low doses of 2–4 mg/kg reduced the memory deficits induced in rats by scopolamine. Much higher doses were necessary to decrease spontaneous motor activity in rats. Since VA21B7 appears to be well tolerated in rodents at high doses, we think that it is of potential interest as an anxiolytic in humans. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

The pharmacology of VA21B7: an atypical 5-HT 3 receptor antagonist with anxiolytic-like properties in animal models

Loading next page...
 
/lp/springer-journals/the-pharmacology-of-va21b7-an-atypical-5-ht-3-receptor-antagonist-with-n5XKLtDHWo
Publisher
Springer Journals
Copyright
Copyright © 1995 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
DOI
10.1007/BF02245179
Publisher site
See Article on Publisher Site

Abstract

213 117 117 2 2 I. Artaiz G. Romero A. Zazpe B. Lasheras J. Del Río A. Monge J. M. Calderó J. Roca Department of Pharmacology, Schools of Medicine and Pharmacy University of Navarra Apdo. 273 E-31080 Pamplona Spain Department of Organic Chemistry, CIFA University of Navarra E-31080 Pamplona Spain Vita Research Department Barcelona Spain Abstract VA21B7 (3-(2-(4′-piperonylpiperazinyl) indolyl) carboxaldehyde) was synthesized as a potential 5-HT 3 receptor antagonist. Even though VA21B7 showed a higher affinity towards 5-HT 3 receptors as compared to other receptors studied, it was not a potent 5-HT 3 receptor antagonist either in the periphery or in the brain. In a simple animal model of anxiety such as the two-compartment box in mice, a remarkable anxiolytic-like effect was found at doses of 2–500 µg/kg IP and also at low oral doses, in the microgram range. These drug doses did not produce any significant effect on spontaneous motor activity of mice. The anxiolytic profile of VA21B7 was further explored using other models of anxiety in rats such as the elevated plus-maze and punished-drinking. VA21B7 was compared with standard 5-HT 3 receptor antagonists such as ondansetron, tropisetron and granisetron, with the 5-HT 1A agent buspirone and with diazepam. In the plus-maze, VA21B7 showed an anxiolytic-like profile after doses of 0.25–0.5 mg/kg IP or 2–4 mg/kg PO which did not modify the number of total entries into the open and closed arms of the maze. Diazepam, granisetron and tropisetron were also effective in this test but not ondansetron and buspirone. VA21B7 was also able to release suppressed behaviour in the punished-drinking test. The dose-response curve was bell-shaped with a peak at 2–4 mg/kg. At variance with other studies, 5-HT 3 receptor antagonists also increased the number of shocks taken in this test and the dose-response curve was also bell-shaped. VA21B7 was not anticonvulsant like diazepam, its anxiolytic action in the light/dark test was not flumazenil-sensitive and there was no rebound anxiogenic effect on withdrawal from chronic VA21B7 treatment for 15 consecutive days. Moreover, VA21B7 was not amnesic like the benzodiazepines but low doses of 2–4 mg/kg reduced the memory deficits induced in rats by scopolamine. Much higher doses were necessary to decrease spontaneous motor activity in rats. Since VA21B7 appears to be well tolerated in rodents at high doses, we think that it is of potential interest as an anxiolytic in humans.

Journal

PsychopharmacologySpringer Journals

Published: Jan 1, 1995

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off